Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMT5VXF)

Drug Name

Revatropate Drug Info

Synonyms

UK-112166; UK-112,166; UK-112166-04; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; (3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 1	[1]

Cross-matching ID

PubChem CID: 9690123
TTD Drug ID: DMT5VXF

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M3 (CHRM3)	TTQ13Z5	ACM3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Chronic obstructive pulmonary disease

ICD Disease Classification

CA22

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M3 (CHRM3)	DTT	CHRM3	4.61E-07	-0.59	-0.73

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
2	Discovery & development of selective M3 antagonists for clinical use.Life Sci.1997;60(13-14):1053-60.